Research

  • Phase 3, double blind, randomized, controlled, study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 mth) in healthy adult female subjects aged 26 years and above (HPV-015) (2009-2014) (NCT00294047) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT00294047.
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (Morab-0003) in Combination with Carboplatin and Taxane in Subjects with Platinum-Sensitive-Ovarian Cancer in First Relapse. (2009-2012) (NCT00849667) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT00849667.
  • Integrated Molecular Analysis of Cancer in Gynaecologic Oncology (IMAC-GO) – 2014 – (NCT02078544) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT02078544.
  • A Randomized Phase II / III Trial of Intravenous (IV) paclitaxel weekly plus (IV) Carboplatin once every 3 weeks versus IV paclitaxel weekly plus intraperitoneal (IP) carboplatin once every 3 weeks in women with epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer – 2014, collaboration with Japan (GOTIC and JGOG) – (NCT01506856) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT01506856.
  • An Open-Label, Single-Arm Phase 2 Clinical Trial of Regorafenib in Patients with Multiply Recurrent Epithelial Ovarian Cancer – 2016 – (NCT02736305) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT02736305.
  • Phase II Study of Vinorelbine in Stem-A/C5-like Subtype Platinum Resistant Ovarian Cancer (VIP trial) – 2017, collaboration with Australia (ANZGOG) – (NCT03188159) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT03188159.
  • A Phase Ib/IIa Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy in Patients with Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin – 2017 – (NCT03100006) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT03100006.
  • A Multicentre Phase II randomised trial of MEDI4736 (DURVALUMAB) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinomas – 2018, collaboration with Korea (KGOG) and Australia (ANZGOG) (NCT03405454) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT03405454.